SINOMAB BIO-B (03681.HK) Schedules 23 March 2026 Board Meeting to Approve FY2025 Final Results

Bulletin Express
03/10

Hong Kong, 10 Mar 2026—SinoMab BioScience Limited (stock code: 03681, abbreviated as “SINOMAB BIO-B”) has announced that its Board of Directors will convene on 23 Mar 2026. The meeting’s primary agenda is to consider and approve the Group’s audited financial results for the fiscal year ended 31 Dec 2025 and to authorise their publication. Additional corporate matters may also be discussed.

The notice was issued by Dr. Shui On Leung, who currently serves as Executive Director, Chairman, and Chief Executive Officer. As of the announcement date, the Board comprises:

• Executive Director: Dr. Shui On Leung • Non-Executive Directors: Dr. Haigang Chen, Mr. Xun Dong, Ms. Xiaosu Wang, Dr. Jianmin Zhang • Independent Non-Executive Directors: Mr. George William Hunter Cautherley, Mr. Ping Cho Terence Hon, Dr. Chi Ming Lee, Ms. Chi Sau Giselle Lee, Mr. Nan Shen

Investors can expect the company’s FY2025 performance figures following Board approval and subsequent publication.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10